梅花生物（600873）：公司将积极应诉，海外布局加速推进

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 13.44 CNY based on a PE of 11.79 for 2025 [13]. Core Insights - The company is actively responding to legal challenges, specifically a lawsuit from Ajinomoto Co., Inc., with an involved amount of 130 million CNY for two cases [13]. - The consolidation of Xiehe Fermentation is expected to enhance earnings, with an estimated increase in non-recurring income of approximately 780 million CNY for the fiscal year 2025 [13]. - The company is accelerating its overseas capacity expansion, having successfully completed the acquisition of Xiehe Fermentation's related businesses, which will enhance its product pipeline and international market presence [13]. Financial Summary - Total revenue is projected to decline slightly from 27,761 million CNY in 2023 to 25,069 million CNY in 2024, before recovering to 30,048 million CNY by 2027, reflecting a CAGR of 4.5% from 2024 to 2027 [4]. - Net profit attributable to the parent company is expected to decrease from 3,181 million CNY in 2023 to 2,740 million CNY in 2024, with a recovery to 3,728 million CNY by 2027 [4]. - The company's earnings per share (EPS) is forecasted to be 1.14 CNY in 2025, with a projected PE ratio of 9.09 [4][14]. Market Data - The current stock price is 10.37 CNY, with a market capitalization of 29,080 million CNY [6][7]. - The stock has a 52-week price range of 9.14 CNY to 11.65 CNY [7]. - The company has a net asset value per share of 5.75 CNY, resulting in a price-to-book ratio of 1.8 [8].